Merck Sharp & Dohme LLC
Belzutifan
Carcinoma, Renal Cell
Countdown
114days
Phase 3 readout · Oct 28, 2026
What's at stake
Phase 3 trial results for Belzutifan in Carcinoma, Renal Cell are due Oct 28, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 13h ago
“CT.gov NCT05239728: Phase 3 trial, sponsor Merck Sharp & Dohme LLC, drug Belzutifan. Primary completion date 2026-10-28 (estimated).”